questionsmedicales.fr
Composés hétérocycliques
Composés hétérocycliques à cycles fusionnés
Composés hétérobicycliques
Indolizine
Indolizidines
Alcaloïdes indoliques
Alcaloïdes formés par condensation de sécologanine et de tryptamine
Alcaloïdes de Vinca
Vinblastine
Vinblastine : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
2
Vinblastine
Cancer
Diagnostic médical
Tests de laboratoire
Imagerie médicale
Vinblastine
Symptômes
2
Effets secondaires
Vinblastine
Nausées
Douleur
Vinblastine
Effets indésirables
Prévention
2
Prévention du cancer
Vinblastine
Traitement
Effets secondaires
Vinblastine
Médicaments antiémétiques
Traitements
2
Lymphome
Cancer du poumon
Vinblastine
Administration intraveineuse
Vinblastine
Traitement du cancer
Complications
2
Complications
Vinblastine
Infections
Moelle osseuse
Vinblastine
Dépression médullaire
Facteurs de risque
2
Facteurs de risque
Vinblastine
Maladies cardiaques
Vinblastine
Pédiatrie
Traitement du cancer
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Vinblastine : Questions médicales les plus fréquentes",
"headline": "Vinblastine : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Vinblastine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-10",
"dateModified": "2025-05-05",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Vinblastine"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Alcaloïdes de Vinca",
"url": "https://questionsmedicales.fr/mesh/D014748",
"about": {
"@type": "MedicalCondition",
"name": "Alcaloïdes de Vinca",
"code": {
"@type": "MedicalCode",
"code": "D014748",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.496.500.500.681.827"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Vinblastine",
"alternateName": "Vinblastine",
"code": {
"@type": "MedicalCode",
"code": "D014747",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Christine Chevreau",
"url": "https://questionsmedicales.fr/author/Christine%20Chevreau",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine, Oncopole, Toulouse, France."
}
},
{
"@type": "Person",
"name": "Stéphane Culine",
"url": "https://questionsmedicales.fr/author/St%C3%A9phane%20Culine",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Oncology Saint-Louis University Hospital, AP-HP, Paris, France. Electronic address: stephane.culine@aphp.fr."
}
},
{
"@type": "Person",
"name": "Gwenaelle Gravis",
"url": "https://questionsmedicales.fr/author/Gwenaelle%20Gravis",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Oncology, Paoli Calmettes Institute, Marseille, France."
}
},
{
"@type": "Person",
"name": "Florence Joly",
"url": "https://questionsmedicales.fr/author/Florence%20Joly",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Oncology, François Baclesse Cancer Center, Caen, France."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Neoadjuvant chemotherapy followed by radical trachelectomy versus upfront abdominal radical trachelectomy for patients with FIGO 2018 stage IB2 cervical cancer.",
"datePublished": "2022-12-20",
"url": "https://questionsmedicales.fr/article/36543029",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ygyno.2022.12.002"
}
},
{
"@type": "ScholarlyArticle",
"name": "Surgical procedures and techniques in robot-assisted uterine artery-preserving radical trachelectomy.",
"datePublished": "2024-05-25",
"url": "https://questionsmedicales.fr/article/38795189",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11701-024-01982-y"
}
},
{
"@type": "ScholarlyArticle",
"name": "Performing a radical trachelectomy with uterine transposition in a patient with stage IB2 cervical cancer: A case report.",
"datePublished": "2023-01-07",
"url": "https://questionsmedicales.fr/article/36638644",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ctarc.2023.100681"
}
},
{
"@type": "ScholarlyArticle",
"name": "The oncological and obstetric results of radical trachelectomy as a fertility-sparing therapy in early-stage cervical cancer patients.",
"datePublished": "2022-10-26",
"url": "https://questionsmedicales.fr/article/36289488",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12905-022-01990-w"
}
},
{
"@type": "ScholarlyArticle",
"name": "Fertility-sparing surgery in early-stage cervical cancer: laparoscopic versus abdominal radical trachelectomy.",
"datePublished": "2022-06-18",
"url": "https://questionsmedicales.fr/article/35717185",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12905-022-01826-7"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés hétérocycliques",
"item": "https://questionsmedicales.fr/mesh/D006571"
},
{
"@type": "ListItem",
"position": 3,
"name": "Composés hétérocycliques à cycles fusionnés",
"item": "https://questionsmedicales.fr/mesh/D000072471"
},
{
"@type": "ListItem",
"position": 4,
"name": "Composés hétérobicycliques",
"item": "https://questionsmedicales.fr/mesh/D006574"
},
{
"@type": "ListItem",
"position": 5,
"name": "Indolizine",
"item": "https://questionsmedicales.fr/mesh/D007212"
},
{
"@type": "ListItem",
"position": 6,
"name": "Indolizidines",
"item": "https://questionsmedicales.fr/mesh/D054836"
},
{
"@type": "ListItem",
"position": 7,
"name": "Alcaloïdes indoliques",
"item": "https://questionsmedicales.fr/mesh/D026121"
},
{
"@type": "ListItem",
"position": 8,
"name": "Alcaloïdes formés par condensation de sécologanine et de tryptamine",
"item": "https://questionsmedicales.fr/mesh/D046948"
},
{
"@type": "ListItem",
"position": 9,
"name": "Alcaloïdes de Vinca",
"item": "https://questionsmedicales.fr/mesh/D014748"
},
{
"@type": "ListItem",
"position": 10,
"name": "Vinblastine",
"item": "https://questionsmedicales.fr/mesh/D014747"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Vinblastine - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Vinblastine",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Vinblastine",
"description": "Comment la vinblastine est-elle utilisée dans le diagnostic du cancer ?\nQuels tests précèdent l'administration de vinblastine ?",
"url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Trachelectomy#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Vinblastine",
"description": "Quels sont les effets secondaires courants de la vinblastine ?\nLa vinblastine provoque-t-elle des douleurs ?",
"url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Trachelectomy#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Vinblastine",
"description": "La vinblastine a-t-elle un rôle préventif dans le cancer ?\nPeut-on prévenir les effets secondaires de la vinblastine ?",
"url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Trachelectomy#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Vinblastine",
"description": "Dans quels types de cancer la vinblastine est-elle utilisée ?\nComment la vinblastine est-elle administrée ?",
"url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Trachelectomy#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Vinblastine",
"description": "Quelles complications peuvent survenir avec la vinblastine ?\nLa vinblastine peut-elle affecter la moelle osseuse ?",
"url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Trachelectomy#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Vinblastine",
"description": "Qui est à risque d'effets indésirables avec la vinblastine ?\nLes enfants peuvent-ils prendre de la vinblastine ?",
"url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Trachelectomy#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment la vinblastine est-elle utilisée dans le diagnostic du cancer ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "La vinblastine n'est pas un outil de diagnostic, mais un traitement pour les cancers diagnostiqués."
}
},
{
"@type": "Question",
"name": "Quels tests précèdent l'administration de vinblastine ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et d'imagerie sont effectués pour évaluer la maladie avant le traitement."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires courants de la vinblastine ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent nausées, vomissements, fatigue et perte de cheveux."
}
},
{
"@type": "Question",
"name": "La vinblastine provoque-t-elle des douleurs ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut causer des douleurs musculaires ou articulaires, mais ce n'est pas systématique."
}
},
{
"@type": "Question",
"name": "La vinblastine a-t-elle un rôle préventif dans le cancer ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, la vinblastine est un traitement et ne prévient pas le développement du cancer."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les effets secondaires de la vinblastine ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments antiémétiques peuvent aider à réduire les nausées causées par la vinblastine."
}
},
{
"@type": "Question",
"name": "Dans quels types de cancer la vinblastine est-elle utilisée ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle est utilisée pour traiter les lymphomes, le cancer du poumon et le cancer du testicule."
}
},
{
"@type": "Question",
"name": "Comment la vinblastine est-elle administrée ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "La vinblastine est généralement administrée par injection intraveineuse sous supervision médicale."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec la vinblastine ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des infections, des saignements et des problèmes neurologiques."
}
},
{
"@type": "Question",
"name": "La vinblastine peut-elle affecter la moelle osseuse ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la vinblastine peut entraîner une dépression de la moelle osseuse, réduisant les globules blancs."
}
},
{
"@type": "Question",
"name": "Qui est à risque d'effets indésirables avec la vinblastine ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients avec des antécédents de maladies cardiaques ou hépatiques sont à risque accru."
}
},
{
"@type": "Question",
"name": "Les enfants peuvent-ils prendre de la vinblastine ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la vinblastine peut être administrée aux enfants, mais avec précaution et surveillance."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 05/05/2025
Contenu vérifié selon les dernières recommandations médicales
4 publications dans cette catégorie
Publications dans "Vinblastine" :
Stem Cell Transplantation and Vinblastine Monotherapy for Relapsed Pediatric Anaplastic Large Cell Lymphoma: Results of the International, Prospective ALCL-Relapse Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2020-07-30
Doxorubicin, vinblastine, dacarbazine and lenalidomide for older Hodgkin lymphoma patients: final results of a German Hodgkin Study Group (GHSG) phase-I trial.
British journal of haematology
2018-12-28
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
The Lancet. Oncology
2023-12-21
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022-03-07
4 publications dans cette catégorie
Affiliations :
Department of Medicine, Oncopole, Toulouse, France.
Publications dans "Vinblastine" :
Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study.
The Lancet. Oncology
2019-07-19
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
Clinical genitourinary cancer
2021-02-24
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
The Lancet. Oncology
2023-12-21
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022-03-07
3 publications dans cette catégorie
Affiliations :
Department of Medical Oncology Saint-Louis University Hospital, AP-HP, Paris, France. Electronic address: stephane.culine@aphp.fr.
Publications dans "Vinblastine" :
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
Clinical genitourinary cancer
2021-02-24
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
The Lancet. Oncology
2023-12-21
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022-03-07
3 publications dans cette catégorie
Affiliations :
Department of Medical Oncology, Paoli Calmettes Institute, Marseille, France.
Publications dans "Vinblastine" :
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
Clinical genitourinary cancer
2021-02-24
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
The Lancet. Oncology
2023-12-21
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022-03-07
3 publications dans cette catégorie
Affiliations :
Department of Medical Oncology, François Baclesse Cancer Center, Caen, France.
Publications dans "Vinblastine" :
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
Clinical genitourinary cancer
2021-02-24
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
The Lancet. Oncology
2023-12-21
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022-03-07
3 publications dans cette catégorie
Affiliations :
Department of Medical Oncology, Jean Perrin Cancer Center, Clermont-Ferrand, France.
Publications dans "Vinblastine" :
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
Clinical genitourinary cancer
2021-02-24
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
The Lancet. Oncology
2023-12-21
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022-03-07
3 publications dans cette catégorie
Affiliations :
Department of Medical Oncology, Lucien Neuwirth Cancer Institute, Saint-Priest-en-Jarez, France.
Publications dans "Vinblastine" :
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
Clinical genitourinary cancer
2021-02-24
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
The Lancet. Oncology
2023-12-21
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022-03-07
3 publications dans cette catégorie
Affiliations :
Department of Pathology, René Huguenin Curie Institute, Saint Cloud, France.
Publications dans "Vinblastine" :
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
Clinical genitourinary cancer
2021-02-24
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
The Lancet. Oncology
2023-12-21
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022-03-07
2 publications dans cette catégorie
Affiliations :
Programme in Developmental and Stem Cell Biology, Division of Haematology/Oncology, Hospital for Sick Children, Toronto, Ontario, Canada.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Plant Production Department, College of Food and Agriculture Sciences, King Saud University, Riyadh 11451, Saudi Arabia.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Department of Natural Product Biosynthesis, Max Planck Institute for Chemical Ecology, Jena, Germany.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Massachusetts General Hospital Cancer Center, Boston, MA.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, UK.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Department of Small Animal Clinical Sciences, Department of Veterinary Anatomy Physiology and Pathology, Institute of Infection Veterinary and Ecological Sciences, University of Liverpool, Chester High Rd, Neston CH64 7TE, UK.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Department of Rehabilitation Medicine, Nagoya University Hospital, Nagoya, Japan.
Department of Orthopaedic Surgery, Nagoya University Hospital, Nagoya, Japan.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Department of Orthopaedic Surgery, Nagoya University Hospital, Nagoya, Japan.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Department of Orthopaedic Surgery, Nagoya University Hospital, Nagoya, Japan.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Department of Orthopaedic Surgery, Nagoya University Hospital, Nagoya, Japan.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Bioanalysis, Department of Pharmaceutical Chemistry, Drug Analysis and Radiopharmacy, Medical University of Lodz, ul. Muszyńskiego 1, 90-151, Lodz, Poland; Department of Applied Pharmacy, Medical University of Lodz, ul. Muszyńskiego 1, 90-151, Lodz, Poland.
Publications dans "Vinblastine" :
To explore the optimal fertility-sparing treatment for stage IB2 cervical cancer. We compared the outcomes of neoadjuvant chemotherapy (NACT) followed by radical trachelectomy (RT) with those of upfro...
This is a retrospective study with prospectively collected data between August 2015 and July 2019. Patients with IB2 cervical cancer who desired fertility preservation underwent NACT followed by RT, o...
This study included 51 patients, of which, 16 patients underwent NACT followed by RT and 35 patients chose upfront ART. Fertility was preserved in 12 (75.0%) and 27 (77.1%) patients from the NACT and ...
NACT followed by RT could be a feasible fertility-sparing option for selected patients with 1B2 cervical cancer. The NACT group had a relatively higher recurrence rate and fewer complications compared...
The aim of the study was to study robotic cervical radical trachelectomy, aimed at standardizing and optimizing surgical procedures, thereby facilitating the learning process. All surgical procedures ...
We describe a case of a woman with invasive IB2 cervical cancer who desired to maintain fertility and required complex treatment. The suggested surgical approach with uterine transposition improves th...
This study explored the oncological and obstetric results of radical trachelectomy (RT) in early-stage cervical cancer patients....
A retrospective analysis was conducted the oncological and obstetric results of 23 patients with early cervical cancer (stages IA2-IB3; International Federation of Gynecology and Obstetrics, 2018) who...
23 patients had cervical tumors of the squamous cell carcinoma histological type. All 23 patients retained reproductive function. The mean follow-up time was 112.87 ± 55.75 (36-199) months. The median...
Radical trachelectomy is a safe and effective treatment for women with early-stage cervical cancer preserving fertility biology. Patients with a cervical tumor sized > 4 cm can be pregnant after neoad...
Radical trachelectomy is an acceptable alternative to radical hysterectomy for patients with early-stage cervical cancer who wish to preserve reproductive function. This study is designed to compare t...
We retrospectively analyzed all early-stage cervical cancer patients who underwent abdominal radical trachelectomy (ART) or laparoscopic radical trachelectomy (LRT) between January 2005 and June 2017 ...
A total of 33 patients (5 with IA1, 2 with IA2, and 26 with 1B1) were included, including 18 patients treated with ART and 15 patients treated with LRT. The median age at initial diagnosis was 30.00 ±...
There is no statistically significant difference in oncological outcome between the two surgical approaches. The clinical pregnancy rate in the ART group was significant higher than that in the LRT gr...
In previous systematic reviews, meta-analysis was lacking, resulting in the statistical difference between the data of different surgeries being impossible to judge. This meta-analysis aims to contras...
We systematically searched databases including PubMed, Embase, Cochrane, and Scopus to collect studies that included open and minimally invasive radical trachelectomy. A random-effect model calculated...
Eight studies (1369 patients) were incorporated into our study. For fertility results, the Open group excels MIS group in pregnancies-Third trimester delivery [OR = 2.68; 95% CI (1.29, 5.59); P = 0.00...
This meta-analysis suggested that the fertility result of the Open group may be better than the MIS group, while the MIS group has better surgery-related outcomes. Owing to the poor cases of our study...
PROSPERO CRD42022352999....
To apply the International Federation of Gynecology and Obstetrics (FIGO) 2018 staging system to all patients who underwent trachelectomy in our previous study and to update the oncologic and obstetri...
We retrospectively reviewed the medical records of patients in whom abdominal trachelectomy was attempted between June 2005 and September 2021. The FIGO 2018 staging system for cervical cancer was app...
Abdominal trachelectomy was attempted for 265 patients. Trachelectomy was converted to hysterectomy in 35 patients, and trachelectomy was completed successfully in 230 (conversion rate: 13%). Applying...
This study suggested that patients judged to be ineligible for trachelectomy and patients receiving overtreatment will continue to appear using the current standard eligibility criteria. With the revi...
Management of early-stage cervical cancer (CC) in young women often faces challenges to preserve fertility, as well as to achieve an adequate oncological outcome. Although existing evidence supports a...
Simple or radical trachelectomy are accepted fertility sparing therapies for patients diagnosed with cervical cancer ≤2 cm. In patients with larger tumors a fertility sparing concept is considered exp...
We retrospectively analyzed the demographic, histological, fertility and follow-up data of all patients with cervical cancer assessed as stage IB2, IB3 or IIA1 under the International Federation of Gy...
A total of 31 patients (mean age 29.5 years, range; 26-40) underwent neoadjuvant chemotherapy followed by radical vaginal trachelectomy in case of proven tumor-free lymph nodes. Twenty-six (84%) of th...
Neoadjuvant chemotherapy followed by radical vaginal trachelectomy may be offered to patients seeking motherhood with cervical cancer >2 cm and histopathologically tumor-free lymph nodes, the rate of ...
Abdominal trachelectomy (AT) is a fertility-preservation surgery for patients with early-stage cervical cancer. Few studies have reported the outcomes of assisted reproductive technology (ART) in pati...
In this retrospective study, we compared the ART outcomes of 13 patients who underwent AT at another hospital prior to undergoing ART at our clinic (T group) and 52 control patients (non-T group) who ...
Cumulative live birth rates were 62% (8/13) and 65% (34/52) in the T and non-T groups, respectively (p = 0.795). The total number of oocyte retrieval cycles was 34 in the T group and 95 in the non-T g...
The pregnancy rate per ET was lower in patients with vs. without a history of AT. Clinicians should be aware of the longer time to pregnancy in patients who undergo ART after AT....